Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
04.11. | Thiogenesis Therapeutics Corp: Thiogenesis receives patent in Europe | 2 | Stockwatch | ||
04.11. | Thiogenesis Therapeutics, Corp.: Thiogenesis Announces Important Core Patent Allowed in Europe | 213 | Newsfile | San Diego, California--(Newsfile Corp. - November 4, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing novel thiol... ► Artikel lesen | |
28.09. | Thiogenesis Therapeutics Corp: Thiogenesis hires Triomphe for IR services | 2 | Stockwatch | ||
27.09. | Thiogenesis Therapeutics, Corp.: Thiogenesis Announces Investor Relations Engagement | 727 | Newsfile | San Diego, California--(Newsfile Corp. - September 27, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (Thiogenesis or the Company) a clinical-stage biotechnology company developing thiol-active... ► Artikel lesen | |
17.09. | Thiogenesis Therapeutics, Corp.: Thiogenesis Announces Presentation at 3rd Annual Leigh Syndrome Symposium | 406 | Newsfile | San Diego, California--(Newsfile Corp. - September 17, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides... ► Artikel lesen | |
20.08. | Thiogenesis Therapeutics Corp: Thiogenesis signs agreement with UCSD | 1 | Stockwatch | ||
THIOGENESIS THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
20.08. | Thiogenesis Therapeutics, Corp.: Thiogenesis Announces Collaboration and Updates on Pediatric NASH Clinical Program | 205 | Newsfile | San Diego, California--(Newsfile Corp. - August 20, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides... ► Artikel lesen | |
18.07. | Thiogenesis Therapeutics Corp: Thiogenesis signs research deal for its Leigh compound | 2 | Stockwatch | ||
18.07. | Thiogenesis Therapeutics, Corp.: Thiogenesis Announces Leigh Syndrome Clinical Program | 347 | Newsfile | San Diego, California--(Newsfile Corp. - July 18, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides that... ► Artikel lesen | |
25.03. | Thiogenesis Therapeutics, Corp.: Thiogenesis Announces Acceptance of Clinical Trial Application - Part I in the EU for MELAS | 320 | Newsfile | San Diego, California--(Newsfile Corp. - March 25, 2024) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides... ► Artikel lesen | |
20.12.23 | Thiogenesis Therapeutics, Corp.: Thiogenesis Announces Closing of Final Tranche in $4.5 Million Non-Brokered Private Placement | 402 | Newsfile | San Diego, California--(Newsfile Corp. - December 20, 2023) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") is very pleased to announce that, further to its news release... ► Artikel lesen | |
17.12.23 | Thiogenesis Therapeutics, Corp.: Thiogenesis Announces Closing of Non-Brokered Private Placement of Common Shares and Insider Participation | 210 | Newsfile | San Diego, California--(Newsfile Corp. - December 18, 2023) - Further to its news release of November 20, 2023, Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") is very... ► Artikel lesen | |
04.12.23 | Thiogenesis Therapeutics, Corp.: Thiogenesis CEO Invited to Lead a Round Table Discussion at Influential Mitochondria Symposium | 615 | Newsfile | San Diego, California--(Newsfile Corp. - December 4, 2023) - Thiogenesis Therapeutics Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company that is developing sulfur-containing... ► Artikel lesen | |
27.11.23 | Thiogenesis Therapeutics, Corp.: Thiogenesis Announces Addition of Dr. Vince Stanton Jr. to Its Scientific Advisory Board | 550 | Newsfile | San Diego, California--(Newsfile Corp. - November 27, 2023) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing sulfur-containing... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 40,120 | +3,30 % | Neue 6,00% Aktienanleihe mit Barriere auf QIAGEN in Zeichnung | München (www.anleihencheck.de) - Die Experten vom Zertifikate-Team der Bank Vontobel Europe AG bieten eine neue Aktienanleihe (ISIN DE000VC7RDU1/ WKN VC7RDU) mit Barriere auf die Aktie von QIAGEN (ISIN... ► Artikel lesen | |
EVOTEC | 9,895 | -0,10 % | Märkte am Morgen: Bitcoin, Talanx, Evotec, ASML, Infineon, Domino's Pizza, Palantir | Der DAX sich gestern von seiner starken Seite präsentiert und kräftig zugelegt. Am Ende ging der Leitindex 1,37 Prozent höher bei 19.263 Punkten aus dem Handel. Heute muss er mit unterschiedlichen Vorgabe... ► Artikel lesen | |
RELAY THERAPEUTICS | 4,660 | 0,00 % | Aktie von Relay Therapeutics erreicht 52-Wochen-Tief bei 5,59 US-Dollar | ||
CULLINAN THERAPEUTICS | 12,580 | 0,00 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 | Cullinan will present new in vitro preclinical data that provide further strong rationale for broad clinical development of CLN-978 in autoimmune diseases Cullinan will share details of global Phase... ► Artikel lesen | |
GALAPAGOS NV | 24,060 | +0,08 % | GALAPAGOS NV - S-8, Securities to be offered to employees in employee benefit plans | ||
BIONTECH | 97,20 | -0,41 % | BioNTech-Aktie: Was bringt diese Übernahme? | Die BioNTech-Aktie hat am Mittwoch um fast +5% auf 111,48 US$ zugelegt, nachdem die Mainzer eine insgesamt fast eine Milliarde US$ schwere Übernahme bekannt gegeben haben. Was steckt hinter diesem Deal?... ► Artikel lesen | |
TECTONIC THERAPEUTIC | 44,030 | 0,00 % | Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion Protein | Phase 1a results support further development of TX000045 ("TX45") for Group 2 Pulmonary Hypertension in HFpEF ("PH-HFpEF"), based on favorable pharmacokinetic profile and impact on renal plasma flow... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,865 | -2,90 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
ARS PHARMACEUTICALS | 13,540 | 0,00 % | James E. Flynn Sells 528,456 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock | ||
GUBRA | 82,20 | +0,74 % | AKTIONÄR-Depotwert Gubra: Die Katze ist aus dem Sack! | Am Mittwoch nach Börsenschluss in Kopenhagen hat der Wirkstoffforscher Gubra erste Phase-1-Daten zu seinem Adipositas-Hoffnungsträger GUBamy vorgelegt. Diese sind äußerst vielversprechend und sollten... ► Artikel lesen | |
BB BIOTECH | 38,350 | -0,78 % | BB Biotech Erkenntnisse beim Lunch mit Vorständen | Ich war wie versprochen beim Investorenlunch von BB Biotech. Der scheidende Vorstandssprecher Dr. Daniel Koller führte seinen Nachfolger Dr. Christian Koch ein. Wie jedes Jahr hielt Vorstandssprecher... ► Artikel lesen | |
TELIX PHARMACEUTICALS | 13,695 | -3,62 % | Eckert & Ziegler: Top-Deal mit Telix Pharma - die Details! | Der Radiopharma-Markt ist und bleibt mächtig in Bewegung. Das unterfüttert ein neuer Kooperations- und Lizenzvertrag, den der deutsche Player Eckert & Ziegler mit dem australischen Radiopharma-Überflieger... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 43,160 | -1,15 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights | Enrollment in global Phase 3 HARBOR study for del-desiran in DM1 is on track
Avidity initiated biomarker cohort for del-brax FORTITUDE study for FSHD; pursuing a... ► Artikel lesen | |
UPSTREAM BIO | 18,010 | 0,00 % | Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares | WALTHAM, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on... ► Artikel lesen | |
HUMACYTE | 4,510 | +2,27 % | Humacyte, Inc: Humacyte Clinical Results Highlighting Benefit of the ATEV in the Repair of Civilian and Military Arterial Injuries Published in JAMA Surgery |